Agomab Therapeutics

Historical price data

Agomab Therapeutics is building a company focused on treating fibrosis by translating deep expertise in growth factor biology into a pipeline of modulating candidates. Its mission is to develop disease-modifying therapeutics that aim to resolve fibrosis and restore organ function. The company's lead candidate, Ontunisertib (AGMB-129), is in Phase 1 development for fibrostenotic Crohn's disease, supported by a strong leadership team and recent IPO proceeds of approximately $200 million. Agomab's strategy combines internal scientific and development expertise with external partnerships to address pressing medical needs in fibrotic diseases.

Focuses on modulating growth factor biology, initially targeting the TGFβ pathway, to develop disease-modifying therapies that resolve fibrosis and restore organ function using validated modalities.

6 drugs in pipeline

Total raised: $145M

Competes with large biopharma and biotech companies targeting fibrosis through various pathways (e.g., TGFβ, integrins). Differentiation is based on specific focus on growth factor biology and aiming for improved safety profiles to overcome limitations of prior therapies. Niche focus on fibrostenotic Crohn's may offer a clearer initial path.